Gut Microbiome for Multiple Myeloma
(Microbiome Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial aims to study the gut microbiome—the community of bacteria and other microorganisms in the digestive system—in individuals with POEMS syndrome and other plasma cell disorders. Researchers seek to understand how these conditions might affect gut health, particularly before treatments like chemotherapy or stem cell transplants begin. The trial divides participants into groups: those newly diagnosed with conditions such as multiple myeloma and amyloidosis, those in remission from POEMS syndrome, and healthy household members without recent gastrointestinal issues or cancer treatments. Participants should have been diagnosed with one of these conditions but not yet received certain treatments or undergone major gastrointestinal interventions recently.
As an unphased trial, this study offers participants a unique opportunity to contribute to groundbreaking research that could enhance understanding of gut health in plasma cell disorders.
Do I need to stop my current medications to join the trial?
The trial does not specify if you need to stop taking your current medications. However, if you have used antibiotics or had chemotherapy in the last 3 months, you may not be eligible to participate.
Why are researchers excited about this trial?
Researchers are excited about this trial because it explores the gut microbiome's role in plasma cell disorders, including POEMS syndrome, multiple myeloma, and AL amyloidosis. Unlike traditional treatments that focus on chemotherapy, radiation, or stem cell transplants, this study investigates how gut bacteria might influence disease progression and patient health. By understanding these microbiome connections, there could be potential to develop new, non-invasive therapies that complement or enhance existing treatments. This approach could lead to more personalized medicine strategies, tailoring treatments based on an individual's gut microbiome profile.
Who Is on the Research Team?
Angela Dispenzieri, M.D.
Principal Investigator
Mayo Clinic in Rochester
Are You a Good Fit for This Trial?
Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Sample Collection
Stool samples are collected from participants using a self-collection kit
Analysis
Samples are evaluated for characteristics of gut microbiome (α-diversity and β-diversity)
Follow-up
Participants are monitored for changes in gut microbiome characteristics
What Are the Treatments Tested in This Trial?
Interventions
- Non-interventional study
How Is the Trial Designed?
6
Treatment groups
Experimental Treatment
POEMS in remission (no chemotherapy, radiation, or stem cell transplant for 2 years
POEMS at diagnosis (before starting chemotherapy, radiation, or stem cell transplant
Multiple myeloma (before starting chemotherapy, radiation or stem cell transplant
MGUS -not treated newly diagnosed
household member to be a healthy control (no chemotherapy or gastrointestinal illness to participate)
AL amyloidosis (before starting chemotherapy or stem cell transplant)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Mayo Clinic
Lead Sponsor
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.